Speaker illustration

Doctor Matthias M Engelen

University of Leuven, Leuven (Belgium)

Member of:

European Society of Cardiology

After being a young professional athlete, he started med school in 2010. He graduated as a medical doctor in 2017 whereafter he got trained in internal medicine as a junior doctor. His master dissertation looked into the clinical use and consequences of thrombolytic therapy, showing his interest in thrombosis and haemostasis. Just recently, he started working on coagulation in cardiovascular diseases as a PhD researcher.

Heparin is more effective than apixaban in inhibiting in vitro contact activated coagulation

Event: ESC CONGRESS 2020 - The Digital Experience

Topic: Platelets, Haemostasis, Coagulation

Session: Role of Platelets, Inflammation and Endothelial Cells in Vascular Dysfunction

Thumbnail

Trends in indications and outcome in thrombolytic therapy: a retrospective single center study

Event: ESC CONGRESS 2019

Topic: Cardiovascular Pharmacotherapy

Session: Cardiovascular pharmacotherapy

Thumbnail

This platform is supported by

logo Novo Nordisk